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Abstract
The effect of the dietary n-3 long-chain PUFA, DHA (22 : 6n-3), on the growth of pre-term infants is controversial. We tested the effect of
higher-dose DHA (approximately 1 % dietary fatty acids) on the growth of pre-term infants to 18 months corrected age compared with
standard feeding practice (0·2–0·3 % DHA) in a randomised controlled trial. Infants born ,33 weeks gestation (n 657) were randomly allo-
cated to receive breast milk and/or formula with higher DHA or standard DHA according to a concealed schedule stratified for sex and
birth-weight (,1250 and $1250 g). The dietary arachidonic acid content of both diets was constant at approximately 0·4 % total fatty
acids. The intervention was from day 2 to 5 of life until the infant’s expected date of delivery (EDD). Growth was assessed at EDD,
and at 4, 12 and 18 months corrected age. There was no effect of higher DHA on weight or head circumference at any age, but infants
fed higher DHA were 0·7 cm (95 % CI 0·1, 1·4 cm; P¼0·02) longer at 18 months corrected age. There was an interaction effect between
treatment and birth weight strata for weight (P¼0·01) and length (P¼0·04). Higher DHA resulted in increased length in infants born weigh-
ing $1250 g at 4 months corrected age and in both weight and length at 12 and 18 months corrected age. Our data show that DHA up to
1 % total dietary fatty acids does not adversely affect growth.
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Growth is a marker of nutritional adequacy in pre-term
infants when free of the major morbidities. Because postnatal
growth failure is a common occurrence in these infants(1–4)
and is associated with increased morbidity and poorer
neurodevelopmental outcomes(5–8), ensuring adequate
growth through a nutritionally complete diet is vital. The
effect of dietary long-chain PUFA (LCPUFA) on the growth
of pre-term infants is controversial. Some early studies have
*Corresponding author: M. Makrides, fax þ61 8 8239 0267, email maria.makrides@health.sa.gov.au
Abbreviations: AA, arachidonic acid; DINO, docosahexaenoic acid for the improvement of neurodevelopmental outcome in pre-term infants; EDD,
expected date of delivery; LCPUFA, long-chain PUFA.
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suggested that supplementing pre-term formula with the n-3
fatty acids DHA (22 : 6n-3) and EPA (20 : 5n-3) reduced
weight and length gains(9–11). An exploratory analysis(12)
from one of these studies(11) showed a positive association
between the concentration of erythrocyte arachidonic acid
(AA, 20 : 4n-6) and weight and length, leading to the hypoth-
esis that a ‘balanced’ dietary supply of n-6 and n-3 LCPUFA
was necessary to support growth, and that AA should be
added in infant formula when n-3 LCPUFA were present.
However, subsequent studies of LCPUFA-supplemented
formula that included AA and at higher concentrations than
DHA have yielded inconsistent results. Studies have shown
that LCPUFA supplementation had positive effects on
weight(13–15) and length(13,15), no effect on weight(16–18) or
length(14,16–18) or a negative effect on weight and length(19).
Systematic reviews investigating the effects of LCPUFA-
supplemented formula on the growth of pre-term infants
have concluded that there are no clear effects of supplemen-
tation(20,21). However, it is difficult to delineate the relative
effects of DHA and AA as trials with DHA alone or DHA
together with AA were combined. In addition, not all of the
included studies were designed to assess growth, which
requires multiple assessments over time.
The Docosahexaenoic acid for the Improvement of Neuro-
developmental Outcome in pre-term infants (DINO) trial
was designed to evaluate the efficacy and safety of a dose
of DHA that was estimated to match in utero accretion. The
unique nature of the intervention allowed us to evaluate the
effect of varying DHA supplementation when AA was held
constant so that the ratio of DHA:AA ranged from about 1:2
in the control group to 2:1 in the higher DHA group. The pre-
sent study reports the complete growth outcomes from the
DINO trial. An earlier publication has demonstrated develop-
mental benefits of higher DHA treatment with no negative
clinical outcomes(22).
This clinical trial has been registered with the Australian
and New Zealand Clinical Trial Registry. The registration
number is ACTRN12606000327583, and the trial web address
is anzctr.org.au
Experimental methods
The methods have been reported previously(22). Briefly, the
DINO trial was a multi-centre randomised controlled trial
conducted in five Australian perinatal centres. The present
study was conducted according to the guidelines laid down
in the Declaration of Helsinki, and all procedures involving
human subjects were approved by the local human research
ethics committees of each centre (Children, Youth and
Women’s Health Service, North Adelaide, SA, Australia;
Flinders Medical Centre, Bedford Park, SA, Australia; King
Edward Memorial Hospital, Subiaco, WA, Australia; Royal
Women’s Hospital, Parkville, VIC, Australia; Royal Brisbane
and Women’s Hospital, Herston, QLD, Australia). Written
informed consent was obtained from all subjects.
Infants were excluded if they had major congenital or chro-
mosomal abnormalities; were a multiple birth where not all
live births were eligible; were in other trials of fatty acid sup-
plementation or had a lactating mother where tuna oil was
contraindicated (bleeding disorders, anticoagulants).
Interventions
Lactating women allocated to the higher DHA group took six
500 mg DHA-rich tuna oil capsules per d; if formula was
required, infants were given a higher-DHA pre-term formula.
Lactating women allocated to the standard DHA group took
six 500 mg placebo soya oil capsules; if formula was required,
a standard pre-term infant formula was used. This strategy
resulted in infants randomised to higher DHA, receiving
DHA triple that of infants randomised to standard DHA with
AA remaining constant between the two groups. The actual
concentrations of selected fatty acids in human milk and
formula are reported in Table 1.
Outcomes
Weight, length and head circumference were measured at
study entry, weekly until discharge home, at the expected
date of delivery (EDD), and at 4, 12 and 18 months corrected
age. The primary growth measures were absolute measures at
4, 12 and 18 months corrected age. Corrected age is calculated
by subtracting the number of weeks born before 40 weeks of
gestation from the chronological age. We also assessed rates of
increase in weight, length and head circumference between
study entry and EDD. Weight, length and head circumference
were taken by trained research personnel. Weight was
measured to the nearest 5 g on calibrated electronic scales.
Table 1. Long-chain PUFA concentration in human milk and formula†‡
(Mean values and standard deviations of fatty acid as a percentage of total fat)
Higher DHA Standard DHA
Human milk (n 136) Formula Human milk (n 133) Formula
Mean SD Mean SD Mean SD Mean SD
Linoleic acid (18 : 2n-6) 9·83* 2·30 18·74 0·68 10·4* 2·74 18·88 0·71
Arachidonic acid (20 : 4n-6) 0·41 0·08 0·69 0·29 0·40 0·08 0·69 0·22
a-Linolenic acid (18 : 3n-3) 0·96 0·33 1·90 0·62 1·00 0·27 1·92 0·13
DHA (22 : 6n-3) 0·85*** 0·39 1·11** 0·29 0·25*** 0·13 0·42** 0·05
Mean values were significantly different: *P,0·05, **P,0·001, ***P,0·0001.
† A 5 ml sample of breast milk was collected at the expected date of delivery appointment and immediately frozen at 2208C.
‡ Infant formula and human milk fatty acids were analysed according to previously established methods(28).
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Length was measured using a recumbent length board with
one person holding the infant’s head in a vertical position,
with the crown of the head touching the fixed headboard
and a second person extending the legs and firmly placing
the movable footboard against the infant’s heels, and
measured to the nearest 0·1 cm. Head circumference was
taken as the largest occipitofrontal circumference, measured
to the nearest 1 mm using a non-stretch tape measure. Data
on milk or formula type consumed were collected during
the intervention period and post-treatment at 4, 12 and 18
months corrected age. Timing of introduction of solids was
collected at 4 months corrected age.
Randomisation
After receiving written informed consent, mother–infant pairs
were randomised through a computer-driven telephone ran-
domisation service. Stratification occurred by centre, birth
weight (,1250 and $1250 g) and infant’s sex. Multiple
births were randomised according to the sex and birth
weight of the first-born infant.
Blinding
There were four colour-coded groups: two for treatment and
two for control. All capsules were similar in size, shape and
colour. Formula was packaged by colour code. Parents, clini-
cians and all research personnel were blinded to the partici-
pant’s study group.
Sample size
Sample size (n 657) was calculated to determine a clinically
significant difference in the trial’s primary outcome, the
Mental Development Index of the Bayley Scales of Infant Devel-
opment at 18 months corrected age(22). This sample size
allowed us to detect a weight difference of 395 g and a length
difference of 0·86 cm with 80 % power. This represents 3·6 %
of the weight and 1·1 % of the length at 18 months, respectively.
The study was planned to determine differences between
sexes (because of the difference in the rates of growth
between boys and girls) and in infants born weighing
,1250 g, as these are the most vulnerable in terms of
growth. We had 80 % power to detect a 473 g difference in
weight and a 1·3 cm difference in length in these subgroups.
Statistics
All infants were analysed according to the group to which they
were assigned. The a priori level of significance was P,0·05.
Weight, length and head circumference measurements were
converted to Z-scores (standard deviation scores) relative to
the WHO Child Growth Standards(23) using WHO software(24).
To account for dependence due to repeated measurements
over time and multiple infants from the same mother, growth
outcomes were analysed using linear mixed-effects models.
To assess the changes in absolute measures of weight,
length and head circumference (both raw values and
Z-scores) over the scheduled appointments, the effects of treat-
ment group, time (EDD, 4, 12 and 18 months corrected age) and
the interaction between treatment group and time were
modelled. The differences in means at each time point (95 %
CI) are presented, independent of the significance of the inter-
action effect, as these comparisons were a priori of interest.
To assess weekly growth in weight, length and head cir-
cumference, the effects of treatment group, time (corrected
age at measurement) and the interaction between treatment
group and time were modelled. Analyses of weekly growth
were performed for the intervention period only (enrolment
to EDD), as weekly data were available.
In the models, adjustment was made for the potential con-
founders of sex (raw scores) and gestational age at delivery
(raw and Z-scores). A priori subgroup analyses based on
infant’s sex and birth-weight strata were planned as growth
varies according to sex and birth weight. The subgroup ana-
lyses were performed via factorial linear mixed-effects
models to allow testing for an interaction between treatment
and subgroup. All calculations were performed using SAS,
version 9.2 (SAS Institute, Inc., Cary, NC, USA).
Results
The number of infants who were screened for the trial, ran-
domly assigned to receive higher DHA or standard DHA and
had growth assessments at EDD, and at 4, 12 and 18 months
corrected age are shown in Fig. 1. Most trial management
effort was directed at securing high follow-up rates for the
primary neurodevelopmental outcome at 18 months corrected
age (614 infants, 93·5 % of those enrolled)(22). Growth was a
secondary outcome, and where obtaining growth data proved
more difficult, in particular at 12 months corrected age, this
was left optional for families and is reflected in the lower rate
compared with the high follow-up rates at EDD, and at 4 and
18 months corrected age. For example, weight data were
available for 634 infants at EDD, this represents 97 % of the
infants who were originally enrolled in the trial; at 4 months
corrected age, 615 infants (94 %); at 12 months corrected age,
471 infants (72 %) and at 18 months corrected age, 598 infants
(91 %). Despite this, the study represents the largest growth
study of DHA supplementation in pre-term infants.
The trial began on 4 April 2001, and ended with the 18
months corrected age follow-up on 21 September 2007. The
demographic and clinical characteristics of the infants and
their families at randomisation were comparable between
the two groups (Table 2). Median duration of treatment was
comparable between the higher DHA and standard DHA
groups (9·4 (interquartile range 7·9–11·4 weeks) v. 9·4 (inter-
quartile range 8·0–11·6 weeks), respectively). Maternal adher-
ence based on capsule returns was 81·1 % in the higher DHA
group and 81·7 % in the standard DHA group (P¼0·88).
Absolute measures of weight, length and head
circumference
There were no significant differences in weight, length or
head circumference at EDD, 4 or 12 months corrected age
Pre-term infant growth with higher-dose DHA 1637
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or in Z-scores (Table 3). At 18 months corrected age, the
length of the higher DHA group was 0·7 cm greater compared
with that of the standard DHA group (95 % CI 0·1, 1·4 cm,
P¼0·02, adjusted for sex and gestational age; Z ¼ 0·28, 95 %
CI 0·02, 0·54, P¼0·04, adjusted for gestational age; Table 3).
There were no significant differences in weight or head
circumference at this time (Table 3).
A priori subgroup analyses based on the randomisation
strata showed an interaction effect between dietary treatment
and birth weight (,1250 or $1250 g) for weight (P¼0·01) and
length (P¼0·04). For Z-scores, a birth weight strata £ diet
interaction existed for length only (P¼0·03).
Infants born weighing $1250 g and randomised to higher
DHA had a significant increase in weight at 12 and 18
months corrected age compared with infants randomised to
standard DHA (adjusted difference in means 338 g, 95 % CI
89, 587, P¼0·01; 571 g, 95 % CI 254, 888, P¼0·0004, respect-
ively). At 4, 12 and 18 months corrected age, infants in the
same birth-weight strata (born weighing $1250 g) and ran-
domised to higher DHA had significant increases in length
2230 Infants (1966 women)
assessed for eligibility
1573 Infants (1421 women) excluded
709 Did not meet inclusion criteria
350 Gestational age not <33 weeks
77 Enteral feeds for >5 d
75 Unknown reasons
52 Tuna oil contraindicated in mother
76 Congenital abnormalities
20 Multiple births with some infants ineligible
7 Participating in another fatty acid intervention study
52 Parents did not speak English well enough to give 
informed consent
382 Refused to participate
405 Missed for logistical reasons
77 Missed for other/unknown reasons
657 Infants (545 women) randomised
322 Infants (272 women)
randomised to higher-DHA diet
335 Infants (273 women)
randomised to standard-DHA diet
312 Completed treatment to expected
date of delivery
10 Did not complete treatment
 6 Died
 4 Consent withdrawn
328 Completed treatment to expected
date of delivery
 7 Did not complete treatment
 4 Died
 3 Consent withdrawn
4 Months corrected age
 316  Weight (g)
 311 Length (cm)
 311 Head circumference (cm)
Expected date of delivery
 325 Weight (g)
 309 Length (cm)
 318 Head circumference (cm)
4 Months corrected age
 299 Weight (g)
 294 Length (cm)
 289 Head circumference (cm)
Expected date of delivery
 309 Weight (g)
 297 Length (cm)
 304 Head circumference (cm)
12 Months corrected age
 231 Weight (g)
 226 Length (cm)
 125 Head circumference (cm)
12 Months corrected age
 240 Weight (g)
 239 Length (cm)
 231 Head circumference (cm)
18 Months corrected age
 292 Weight (g)
 286 Length (cm)
 282 Head circumference (cm)
18 Months corrected age
 306 Weight (g)
 306 Length (cm)
 305 Head circumference (cm)
Fig. 1. Participant flow through the trial including number of infants assessed for each outcome (weight, length and head circumference) at each time point.
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(adjusted difference in means 0·6 cm, 95 % CI 0·0, 1·2, P¼0·04;
1·1 cm, 95 % CI 0·4, 1·9, P¼0·004; 1·7 cm, 95 % CI 0·9, 2·5,
P¼0·0001, respectively; Z ¼ 0·37, 95 % CI 0·09, 0·65, P¼0·01;
0·46, 95 % CI 0·14, 0·77, P¼0·004; 0·59, 95 % CI 0·26, 0·91,
P¼0·0004, respectively) compared with infants randomised
to standard DHA. For infants born weighing ,1250 g, the
groups did not differ in weight or length. Z-scores by birth-
weight strata are presented in Fig. 2.
There were no interaction effects between dietary treatment
and sex for weight, length or head circumference.
Rate of increase in weight, length and head circumference
from enrolment to expected date of delivery (during the
treatment period)
From enrolment to EDD, there were no differences between
dietary treatment groups in the weekly growth rate in any of
the growth indices such as weight, length and head circumfer-
ence. There was a significant interaction effect (P¼0·01)
between dietary treatment and birth-weight strata for the
rate of head-circumference gain between enrolment and
EDD. The head circumference of infants born weighing
,1250 g and randomised to higher DHA was 0·017 cm/week
greater than that of infants randomised to standard DHA
(95 % CI 0·003, 0·030, P¼0·02, adjusted for gestational age
and sex).
There were no interaction effects between dietary treatment
and birth-weight strata for the rate of increase in weight and
length. Similarly, there were no interaction effects between
dietary treatment and sex for the rate of increase in weight,
length or head circumference.
Post-treatment diet (expected date of delivery
to 18 months corrected age)
There were no differences between randomised groups in the
post-treatment source of milk at 4, 12 or 18 months corrected
age (Table 4). There was no significant difference in the
percentage of infants who had been introduced to solids at
4 months corrected age (59·9 % higher DHA, 53 % control;
adjusted relative risk 1·13, 95 % CI 0·97, 1·33; P¼0·12).
Discussion
In this large-scale trial, we found that infants randomised to
the higher-DHA diet were longer by 0·7 cm at 18 months cor-
rected age compared with infants fed according to current best
practice. This effect was modest (28 % of SD) and occurred 18
months after the intervention finished. Although it is tempting
to speculate that this effect was due to random error, the direc-
tion is consistent with effects observed in some of the pre-
planned subgroup analyses by randomisation strata. Infants
born weighing $1250 g responded to the intervention differ-
ently from those infants with birth weight ,1250 g in the
post-intervention period. There were no differences in post-
intervention growth in infants born weighing ,1250 g, and
those born weighing $1250 g and randomised to higher
DHA had greater mean weights at 12 and 18 months corrected
age and greater mean lengths and mean length Z-scores at 4,
12 and 18 months corrected age. It is unclear that why there
was no effect on post-intervention growth in the lower
birth-weight infants (,1250 g). These infants are sicker and
grow less well generally.
However, during the treatment period from enrolment to
EDD, infants born weighing ,1250 g and randomised to
higher DHA had a significantly greater rate of head growth
than those randomised to standard DHA. Such a small differ-
ence in the rate of head growth (0·017 cm/week, 95 % CI
0·003, 0·030; 0·2 cm over the course of average length of hos-
pitalisation of 12 weeks) would seem unlikely to be of clinical
significance. Nevertheless, it was in this group of infants
where, in unadjusted analyses, a significant increase in the
mental development index was found(22). Observational
studies in very pre-term infants have demonstrated an associ-
ation between the rate of head circumference growth and
improved neurodevelopment in childhood(5,25,26). It is poss-
ible that even such small, yet statistically significant, increases
Table 2. Baseline demographic and clinical characteristics
(Mean values, standard deviations, medians, interquartile ranges, and
percentages)
Higher
DHA
(n 322)
Standard
DHA
(n 335)
n % n %
Recruitment hospital
Flinders Medical Centre 31 9·6 32 9·6
King Edward Memorial Hospital 65 20·2 57 17·0
Royal Brisbane and Women’s Hospital 46 14·3 50 14·9
Royal Women’s Hospital 61 18·9 63 18·8
Women’s and Children’s Hospital 119 37·0 133 39·7
Mother’s age at trial entry (years)
Mean 29·9 30·2
SD 5·8 5·4
Mother completed secondary education 193 59·9 178 53·1
Father completed secondary education 160 49·7 160 47·8
Mother smoked during pregnancy 82 25·5 83 24·8
Previous pre-term births 51 15·8 58 17·4
Birth by caesarean section 220 68·3 234 69·9
Antenatal corticosteroids administered 279 86·6 301 90·1
Multiple pregnancy 98 30·4 123 36·7
Gestational age at birth (weeks)
Median 30 30
Interquartile range 27–31 27–31
Male sex 173 53·7 182 54·3
Birth wt (g)
Mean 1308 1307
SD 423 415
Birth wt ,1250 g 147 45·7 149 44·5
Recumbent length at birth (cm)
Mean 38·2 38·2
SD 4·0 4·1
Head circumference at birth (cm)
Mean 27·2 27·3
SD 2·8 2·7
Days of partial enteral feeds pre-randomisation
Median 2 2
Interquartile range 1–4 0–3
Infant age at randomisation (d)
Median 4 4
Interquartile range 3–6 2–5
Infants receiving breast milk at trial entry 297 92·2 306 91·3
Pre-term infant growth with higher-dose DHA 1639
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Table 3. Weight, length and head circumference at expected date of delivery (EDD), and at 4, 12 and 18 months corrected age with Z-scores*†‡
(Mean values and standard deviations, with difference of means as the treatment effect, n and 95 % confidence intervals)
Higher DHA Standard DHA Unadjusted difference Adjusted difference‡
n Mean SD Mean SD Mean 95 % CI Unadjusted P Mean 95 % CI Adjusted P
Weight (g)
EDD 309/325 3170 553 3120 533 28 2104, 161 0·67 25 2102, 153 0·70
Z-score 20·45 1·15 20·50 1·14 0·01 20·19, 0·21 0·92 0·00 20·19, 0·19 0·97
4 months corrected age 299/316 6218 1013 6203 1059 212 2154, 130 0·87 214 2151, 123 0·84
Z-score 20·78 1·34 20·83 1·37 0·02 20·18, 0·22 0·87 0·01 20·18, 0·20 0·92
12 months corrected age 231/240 9317 1455 9195 1410 92 2119, 304 0·39 78 2127, 284 0·45
Z-score 20·13 1·33 20·27 1·36 0·10 20·12, 0·33 0·37 0·09 20·13, 0·31 0·42
18 months corrected age 292/306 11 029 1764 10 775 1520 176 289, 442 0·19 162 296, 419 0·22
Z-score 0·13 1·26 20·06 1·21 0·14 20·09, 0·38 0·23 0·13 20·09, 0·36 0·25
Length (cm)
EDD 297/309 48·4 2·9 48·3 2·9 0·2 20·4, 0·7 0·56 0·1 20·4, 0·6 0·60
Z-score 20·88 1·51 20·86 1·51 0·02 20·22, 0·25 0·90 0·01 20·22, 0·23 0·96
4 months corrected age 294/311 61·3 3·2 61·2 3·4 0·1 20·4, 0·7 0·60 0·1 20·4, 0·6 0·60
Z-score 20·87 1·46 20·95 1·55 0·08 20·15, 0·32 0·49 0·08 20·15, 0·31 0·50
12 months corrected age 226/239 74·3 3·6 74·1 3·7 0·3 20·3, 1·0 0·27 0·3 20·3, 0·9 0·27
Z-score 20·27 1·43 20·40 1·50 0·16 20·11, 0·42 0·24 0·15 20·10, 0·41 0·24
18 months corrected age 286/306 81·9 4·0 81·2 3·9 0·8 0·1, 1·4 0·02 0·7 0·1, 1·4 0·02
Z-score 0·20 1·35 20·10 1·33 0·28 0·01, 0·55 0·04 0·28 0·02, 0·54 0·04
Head circumference (cm)
EDD 304/318 35·3 1·6 35·2 1·6 0·005 20·3, 0·3 0·97 0·004 20·2, 0·3 0·98
Z-score 0·66 1·22 0·67 1·28 20·04 20·25, 0·16 0·67 20·05 20·24, 0·15 0·64
4 months corrected age 289/312 41·6 1·7 41·8 1·7 20·2 20·4, 0·1 0·20 20·2 20·4, 0·1 0·17
Z-score 0·38 1·31 0·48 1·26 20·12 20·33, 0·08 0·24 20·12 20·32, 0·07 0·22
12 months corrected age 225/231 46·1 1·8 46·2 1·8 20·1 20·4, 0·2 0·48 20·1 20·4, 0·2 0·45
Z-score 0·44 1·29 0·45 1·32 20·05 20·28, 0·17 0·64 20·06 20·28, 0·16 0·61
18 months corrected age 282/305 47·8 1·8 47·8 1·7 20·05 20·4, 0·3 0·76 20·1 20·4, 0·3 0·74
Z-score 0·66 1·26 0·62 1·21 20·02 20·25, 0·21 0·86 20·02 20·25, 0·21 0·84
* Reference data for calculating Z-scores according to the WHO Child Growth Standards(23).
† P values for treatment group-by-time interactions were as follows: weight (0·40 unadjusted, 0·44 adjusted), weight Z-score (0·54 unadjusted, 0·56 adjusted), length (0·11 unadjusted, 0·13 adjusted), length Z-score (0·11 unad-
justed, 0·09 adjusted), head circumference (0·29 unadjusted, 0·27 adjusted) and head circumference Z-score (0·62 unadjusted, 0·63 adjusted).
‡ Raw scores adjusted for gestational age and sex; Z-scores adjusted for gestational age.
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in the rate of head growth may be associated with neurodeve-
lopmental improvement.
At the very least, our data indicate that higher DHA in the
diet of pre-term infants has no negative effects on weight,
length or head circumference during the first 18 months of
life, despite the extreme change of LCPUFA balance in the
early diet of pre-term infants. Unlike other studies, measure-
ments of blood fatty acid status in our infants confirmed that
the higher-DHA diets had resulted in a reduction in the
plasma and erythrocyte membrane phospholipid AA concen-
trations as well as an increase in DHA and EPA in the higher
DHA group compared with the standard DHA treatment(27).
Furthermore, although both groups of infants received dietary
AA, the reduction in plasma and erythrocyte phospholipid AA
observed in the higher DHA group implies that there was an
exchange of AA for DHA and EPA incorporation into phos-
pholipids. The results of the present large study with a
robust design refute the reports of earlier studies, which
suggested that this process may be a factor influencing poor
growth in pre-term infants(9–12).
In comparison with WHO growth reference data that define
ideal growth of children born at term, raised in a good
environment and exclusively breast-fed, the weight and
length of infants born weighing ,1250 g remained below
the expected mean Z-score value of zero, although the
growth of these infants improved with time. Conversely, the
mean head circumference Z-score remained consistently
above zero. In contrast, the growth of infants born weighing
$1250 g was consistent with the WHO standard. While these
data indicate that modern neonatal feeding practices result
in post-term growth comparable with healthy, term infants
for infants born weighing $1250 g, there remains room for
improvement with regard to feeding practices for infants
born weighing ,1250 g.
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Fig. 2. (a, d) Weight, (b, e) length and (c, f) head circumference Z-scores by birth-weight strata (,1250 g (a–c) and $1250 g (d–f)) at expected delivery date
(EDD), and at 4, 12 and 18 months corrected age. Values are means, with standard deviations represented by vertical bars. A birth weight £ diet interaction for
Z-scores existed for length (P¼0·03). Birth-weight strata Z-scores were statistically significantly different: *P¼0·01, **P¼0·004, ***P¼0·0004. A, Higher DHA; o,
standard DHA.
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Many factors influence growth including the genetic poten-
tial of each infant, the in utero and ex utero environment,
including diet, infections and medical treatments. The pro-
portion of infants fed breast milk or formula, the type of
formula and the proportion of infants fed solid foods did
not differ between groups in the present study; however,
more detailed information on dietary intake was not collected.
In this trial of DHA supplementation, we have shown that
high dietary DHA intakes, capable of suppressing AA tissue
incorporation, do not adversely affect the growth of pre-
term infants. This observation may differ from other studies
because all infants received some dietary AA or because
some other studies had methodological limitations that could
not exclude the possibility of bias or random error(9–12). The
modest, positive effects of the higher-DHA diet on different
measures of growth observed in the birth-weight strata are
worthy of further investigation, while the consistent lack of
effect by infant’s sex indicated that higher-DHA diets have
no differential effect on growth by sex.
Acknowledgements
We thank the families, and the medical, nursing and research
staff who participated in each participating centre (the
Women’s and Children’s Hospital; Flinders Medical Centre;
the King Edward Memorial Hospital; the Royal Women’s Hos-
pital; the Royal Brisbane and Women’s Hospital) and the staff
of the Child Nutrition Research Centre and of the Data Man-
agement and Analysis Centre, University of Adelaide, North
Adelaide, Adelaide. In the past, M. M., R. A. G. and K. S.
have conducted clinical trials funded by the formula industry.
They have no financial interest in the production and sales of
infant formula or nutritional supplements. M. M. served on
scientific advisory boards for Nestle´, Fonterra, and Nutricia;
R. A. G. served on scientific advisory boards for Wyeth, Fon-
terra and Nestle´; K. S. served on a scientific advisory board
for Wyeth. Associated honoraria for M. M. and R. A. G. were
paid to their institutions to support conference travel and
continuing education for postgraduate students and early
career researchers. The honorarium for K. S. was paid to her
directly. The present study was supported by a grant from
the Australian National Health and Medical Research Council
(ID 250322). Treatment and placebo capsules were donated
by Clover Corporation, and infant formula was donated by
Mead Johnson Nutritionals and Nutricia Australasia. Research
fellowships were from the National Health and Medical
Research Council of Australia (M. M., R. A. G., P. G. D. and
P. B. C.). None of the funding bodies or companies had any
role in the study design or conduct; data collection, manage-
ment, analysis or interpretation; or preparation, review or
approval of the manuscript. M. M., R. A. G., A. J. M.,
P. G. D., K. S., P. B. C. and S. M. designed the trial. M. M.,
A. J. M., C. T. C., L. W. D., K. S., P. B. C., S. M. and P. R.
were involved in the data collection. C. T. C., M. M., R. A. G.,
A. J. M., T. R. S., P. R., L. W. D., K. S., S. M. and P. G. D. con-
ducted the data analysis and interpretation. C. T. C., M. M. and
R. A. G. were responsible for drafting the manuscript; all
authors critically reviewed the manuscript. Statistical analyses
were conducted by T. R. S. under the supervision of P. R.
References
1. Embleton NE, Pang N & Cooke RJ (2001) Postnatal malnu-
trition and growth retardation: an inevitable consequence
of current recommendations in preterm infants? Pediatrics
107, 270–273.
2. Carlson SJ (1999) Actual nutrient intakes of extremely low-
birthweight infants. In Nutrition of the Very Low Birthweight
Infant, pp. 221–228 [EE Ziegler, A Lucas and GE Moro, edi-
tors]. Philadelphia, PA: Lippincott Williams & Wilkins.
3. Ehrenkranz RA, Younes N, Lemons JA, et al. (1999) Longi-
tudinal growth of hospitalized very low birth weight infants.
Pediatrics 104, 280–289.
4. Fenton TR, McMillan DD & Sauve RS (1990) Nutrition and
growth analysis of very low birth weight infants. Pediatrics
86, 378–383.
Table 4. Milk or formula type post-intervention
(Number of infants and percentages)
4 months corrected age 12 months corrected age 18 months corrected age
Higher DHA
(n 306)
Standard
DHA (n 319)
Higher DHA
(n 295)
Standard
DHA (n 319)
Higher DHA
(n 297)
Standard
DHA (n 313)
n % n % n % n % n % n %
Only breast milk 53 17·3 58 18·2 15 5·1 14 4·4
Only DHA-enriched formula 116 37·9 122 38·2 71 24·1 62 19·4 13 4·4 15 4·8
Both breast milk and DHA-enriched formula 19 6·2 23 7·2
Breast milk and formula and/or cows’ milk 12 4·1 13 4·1 10 3·4 8 2·6
Only non-DHA formula 108 35·3 107 33·5 49 16·6 57 17·9 5 1·7 16 5·1
Non-DHA formula and breast milk or
DHA-enriched formula
10 3·3 9 2·8
Only cows’ milk 103 34·9 116 36·4 217 73·1 234 74·8
Other 45 15·3 57 17·9 52 17·5 40 12·8
Unadjusted P * 0·98 0·86 0·18
Adjusted P *† 0·98 0·85 0·17
* Source of milk compared between groups using log-linear Poisson regression models.
† Adjusted for gestational age and sex.
C. T. Collins et al.1642
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https://doi.org/10.1017/S000711451000509X
Downloaded from https:/www.cambridge.org/core. UQ Library, on 03 Feb 2017 at 03:42:53, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
5. Franz AR, Pohlandt F, Bode H, et al. (2009) Intrauterine,
early neonatal, and postdischarge growth and neurodeve-
lopmental outcome at 5·4 years in extremely preterm infants
after intensive neonatal nutritional support. Pediatrics 123,
e101–e109.
6. Tan M, Abernethy L & Cooke R (2008) Improving head
growth in preterm infants – a randomised controlled trial
II: MRI and developmental outcomes in the first year. Arch
Dis Child Fetal Neonatal Ed 93, F342–F346.
7. Ehrenkranz RA (2007) Early, aggressive nutritional manage-
ment for very low birth weight infants: what is the evidence?
Semin Perinatol 31, 48–55.
8. Latal-Hajnal B, von Siebenthal K, Kovari H, et al. (2003) Post-
natal growth in VLBW infants: significant association with
neurodevelopmental outcome. [see comment]. J Pediatr
143, 163–170.
9. Carlson SE, Werkman SH & Tolley EA (1996) Effect of long-
chain n-3 fatty acid supplementation on visual acuity and
growth of preterm infants with and without bronchopulmon-
ary dysplasia. Am J Clin Nutr 63, 687–697.
10. Ryan AS, Montalto MB, Groh-Wargo S, et al. (1999) Effect of
DHA-containing formula on growth of preterm infants to 59
weeks postmenstrual age. Am J Hum Biol 11, 457–467.
11. Carlson SE, Cooke RJ, Werkman SH, et al. (1992) First year
growth of preterm infants fed standard compared to
marine oil n-3 supplemented formula. Lipids 27, 901–907.
12. Carlson SE, Werkman SH, Peeples JM, et al. (1993) Arachido-
nic acid status correlates with first year growth in preterm
infants. Proc Natl Acad Sci U S A 90, 1073–1077.
13. Clandinin MT, Van Aerde JE, Merkel KL, et al. (2005) Growth
and development of preterm infants fed infant formulas con-
taining docosahexaenoic acid and arachidonic acid. J Pediatr
146, 461–468.
14. Innis SM, Adamkin DH, Hall RT, et al. (2002) Docosahexae-
noic acid and arachidonic acid enhance growth with no
adverse effects in preterm infants fed formula. J Pediatr
140, 547–554.
15. O’Connor DL, Hall R, Adamkin D, et al. (2001) Growth and
development in preterm infants fed long-chain polyunsatu-
rated fatty acids: a prospective, randomized controlled trial.
Pediatrics 108, 359–371.
16. Vanderhoof J, Gross S, Hegyi T, et al. (1999) Evaluation of a
long-chain polyunsaturated fatty acid supplemented formula
on growth, tolerance, and plasma lipids in preterm infants
up to 48 weeks postconceptional age. J Pediatr Gastroen-
terol Nutr 29, 318–326.
17. Clandinin MT, Van Aerde JE, Parrott A, et al. (1997)
Assessment of the efficacious dose of arachidonic and
docosahexaenoic acids in preterm infant formulas: fatty
acid composition of erythrocytemembrane lipids. Pediatr
Res 42, 819–825.
18. Stier C, Hess M, Watzer B, et al. (1997) Prostanoid formation
during feeding of a preterm formula with long-chain polyun-
saturated fatty acids in healthy preterm infants during the
first weeks of life. Pediatr Res 42, 509–513.
19. Fewtrell MS, Morley R, Abbott RA, et al. (2002) Double-blind,
randomized trial of long-chain polyunsaturated fatty acid
supplementation in formula fed to preterm infants. [see com-
ment]. Pediatrics 110, 73–82.
20. Simmer K, Schulzke SM & Patole S (2008) Long chain
polyunsaturated fatty acid supplementation in preterm
infants. The Cochrane Database of Systematic Reviews
2008, issue 1, CD000375. http://www.mrw.interscience.
wiley.com/cochrane/clsysrev/articles/CD000375/frame.html.
21. Rosenfeld E, Beyerlein A, Hadders-Algra M, et al. (2009) IPD
meta-analysis shows no effect of LC-PUFA supplementation
on infant growth at 18 months. Acta Paediatrica 98, 91–97.
22. Makrides M, Gibson RA, McPhee AJ, et al. (2009) Neurodeve-
lopmental outcomes of preterm infants fed high-dose
docosahexaenoic acid: a randomized controlled trial. JAMA
301, 175–182.
23. WHO Multicentre Growth Reference Study Group (2006)
WHO Child Growth Standards based on length/height,
weight and age. Acta Paediatr Suppl 450, 76–85.
24. WHO (2009) Anthro for Personal Computers, Version 3: Soft-
ware for Assessing Growth and Development of the World’s
Children. Geneva: WHO. http://www.who.int/childgrowth/
software/en.
25. Kan E, Roberts G, Anderson PJ, et al. (2008) The association
of growth impairment with neurodevelopmental outcome at
eight years of age in very preterm children. Early Hum Dev
84, 409–416.
26. Ehrenkranz RA, Dusick AM, Vohr BR, et al. (2006) Growth in
the neonatal intensive care unit influences neurodevelop-
mental and growth outcomes of extremely low birth
weight infants. Pediatrics 117, 1253–1261.
27. Smithers LG, Gibson RA, McPhee A, et al. (2008) Effect of
two doses of docosahexaenoic acid (DHA) in the diet of pre-
term infants on infant fatty acid status: results from the DINO
trial. Prostaglandins Leukot Essent Fatty Acids 79, 141–146.
28. Gibson RA, Neumann MA & Makrides M (1997) Effect of
increasing breast milk docosahexaenoic acid on plasma
and erythrocyte phospholipid fatty acids and neural indices
of exclusively breast fed infants. Eur J Clin Nutr 51,
578–584.
Pre-term infant growth with higher-dose DHA 1643
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https://doi.org/10.1017/S000711451000509X
Downloaded from https:/www.cambridge.org/core. UQ Library, on 03 Feb 2017 at 03:42:53, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
